Literature DB >> 27562933

Recommended screening and preventive evaluation practices of adult candidates for hematopoietic stem cell transplantation.

Roberta Fedele1, Nina Salooja2, Massimo Martino1.   

Abstract

INTRODUCTION: Hematopoietic stem cell transplantation (HSCT) is associated with a substantial risk of morbidity and mortality. Better selection of HSCT patients for intensive treatment, and consequently reduction of non-beneficial care, may improve the therapeutic outcome. AREAS COVERED: This manuscript provides a systematic review which examines t he current criteria for selection of HSCT patients. EXPERT OPINION: Identifying patients who may benefit from HSCT involves many factors, including overall health, prior therapies, age, disease, and stage. The decision regarding transplant eligibility should be made on a case by case basis, based on a risk-benefit assessment. The advent of the comorbidity index as a measure of health status at the time of HSCT has facilitated the incorporation of comorbidities into the pre-transplant assessment of patients. Many HSCT protocols are still age-dependent, with criteria limited to patients either younger or older than arbitrary age cut-offs.The prognostic role of age in the transplant setting has never been consistent. As physicians and researchers continue improving the HSCT process and outcomes, optimization of the delivery of a comprehensive treatment plan should become an important component of overall patient management.

Entities:  

Keywords:  Hematopoietic stem cell transplantation; evaluation; hematological malignancies; preparation

Year:  2016        PMID: 27562933     DOI: 10.1080/14712598.2016.1229773

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  2 in total

1.  Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial.

Authors:  Jeremy S Abramson; Tanya Siddiqi; Jacob Garcia; Christine Dehner; Yeonhee Kim; Andy Nguyen; Sophie Snyder; November McGarvey; Matthew Gitlin; Corey Pelletier; Monika P Jun
Journal:  Blood Adv       Date:  2021-03-23

2.  Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials.

Authors:  M Lia Palomba; Monika Parisi Jun; James Lymp; Andy Nguyen; November McGarvey; Matthew Gitlin; Corey Pelletier; Scott J Keating; John Godwin
Journal:  Leuk Lymphoma       Date:  2021-05-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.